I've reviewed many interim updates and full-year reports from ASX biotech stocks. Few come close to this in terms of clarity of message, particularly given the breadth of commercial, clinical and R&D activity TLX is embarking on.
Lots of milestones to look out for on the near and mid-term horizon. Lots for shareholders - current and future - to be excited about.
Ann: Half Year Shareholder Update, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.44 |
Change
-0.320(1.54%) |
Mkt cap ! $6.840B | |||
| Open | High | Low | Value | Volume |
| $20.79 | $21.00 | $20.22 | $19.41M | 945.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $20.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.46 | 45 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |